SAN DIEGO, CA / ACCESSWIRE / December 21, 2023 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a…
Trial Meets Both Primary and Key Secondary EndpointsLAVAL, QC / ACCESSWIRE / December 21, 2023 / Bausch Health Companies Inc.…
GOTHENBURG, SWEDEN / ACCESSWIRE / December 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, December 21, 2023 - IRLAB Therapeutics…
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating…
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL);…
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing…
The network’s physicians’ research reports were selected after a thorough peer review process. AON Physicians Present Research Reports at Annual…
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and…
Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile…
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE)…